No. 1582Independent rewrite deskUpdated September 5, 2026

Financial News
& Market Press Releases

EARNINGSKNOT Offshore Partners adds Hilda Knutsen and refinances $225 million as shuttle tanker supply falls short of demandSep 5GOOGLFairphone Gen 6+ arrives in the US at $650, betting repairability beats the upgrade cycleSep 5NVDAWoot puts refurbished Alienware Aurora 16 within reach at $927Sep 5NVDANvidia's Hugging Face acquisition plan sends Huang's net worth toward $200 billionSep 5DEALSHow the Los Angeles Rams engineered cap room to bring Aaron Donald backSep 4$BTCBlackRock's IBIT hits $70 billion as Fink's Bitcoin view completes its arcSep 4MACROL3Harris Technologies awarded $139 million Navy contract for submarine mastsSep 4REGULATORYCBS Mornings adds Norah O'Donnell as Paramount's $111 billion Warner Bros. Discovery deal faces antitrust trialSep 4$BTCSurprise nonfarm payrolls print sends Bitcoin back below $80,000Sep 4CRYPTOZcash crosses $1,000 as Grayscale ZCSH inflows ramp and miners crowd the networkSep 4EARNINGSKNOT Offshore Partners adds Hilda Knutsen and refinances $225 million as shuttle tanker supply falls short of demandSep 5GOOGLFairphone Gen 6+ arrives in the US at $650, betting repairability beats the upgrade cycleSep 5NVDAWoot puts refurbished Alienware Aurora 16 within reach at $927Sep 5NVDANvidia's Hugging Face acquisition plan sends Huang's net worth toward $200 billionSep 5DEALSHow the Los Angeles Rams engineered cap room to bring Aaron Donald backSep 4$BTCBlackRock's IBIT hits $70 billion as Fink's Bitcoin view completes its arcSep 4MACROL3Harris Technologies awarded $139 million Navy contract for submarine mastsSep 4REGULATORYCBS Mornings adds Norah O'Donnell as Paramount's $111 billion Warner Bros. Discovery deal faces antitrust trialSep 4$BTCSurprise nonfarm payrolls print sends Bitcoin back below $80,000Sep 4CRYPTOZcash crosses $1,000 as Grayscale ZCSH inflows ramp and miners crowd the networkSep 4

NewsDeals · GS

Aurora Cannabis (ACB) in focus as Curaleaf (CURLF) tables unsolicited $4-per-share bid

Curaleaf's unsolicited $4-per-share cash-and-stock bid for Aurora Cannabis (ACB) landed on Aug. 11, after private acquisition talks between the two companies broke down and the U.S. multi-state operator said it would take the proposal directly to Aurora shareholders. Curaleaf (CURLF) formed a special committee to review the offer before that approach. Aurora's board has not accepted the terms, and the next definable event is a formal response from ACB's directors.

By Desmond ChoiNewsroomAugust 14, 20262 min readGS

Curaleaf (CURLF) made an unsolicited $4-per-share cash-and-stock bid for Aurora Cannabis (ACB) on Aug. 11 after private acquisition talks broke down.
Aurora's board has not accepted the offer, calling the price too low and below levels ACB traded at as recently as December 2025.
Curaleaf says the combined company would span 17 countries with over $1.5 billion in annual revenue and at least $40 million in annual cost savings.
Aurora shares traded around $3.48 at the time of the report, a discount to the $4 offer, while Curaleaf shares closed Tuesday about 6% higher.
The next key event is a formal response from Aurora's board and any amended terms from Curaleaf.

Aurora shares were trading around $3.48 at the time of the source report, a discount to the proposed $4. Even with the session move, ACB is still down roughly 10% from the start of the year. Curaleaf shares ended Tuesday about 6% higher.

The strategic logic Curaleaf offered is specific. The acquisition, as the company described it, would create a combined business spanning 17 countries with over $1.5 billion in annual revenue and at least $40 million in annual cost savings. The international footprint is the point: the deal would accelerate Curaleaf's expansion into European medical cannabis markets, including Germany, Poland, and the UK. Aurora's recently acquired Safari Flower Company brings EU-GMP certified cultivation facilities and adds over 50 tons of annual production capacity.

Aurora's board has already signaled the price is too low, noting the proposed valuation falls below levels ACB traded at as recently as December 2025. Wall Street analysts have said the bid undervalues Aurora's long-term medical business. Heading into Aug. 11, the consensus rating on ACB was "Moderate Buy," and price targets reached as high as $5.71.

That analyst ceiling matters for the tape. If Curaleaf holds at $4 and Aurora declines without a higher competing bid materializing, the stock gives those session gains back. Watch for Aurora's formal board response and any amended terms from Curaleaf.

More from the Newsroom

All stories →

01Deals · GOOGL

Fairphone Gen 6+ arrives in the US at $650, betting repairability beats the upgrade cycle

Fairphone, the Dutch smartphone maker, has entered the US market with the Gen 6+, priced at $650 and built around a repairability-first design that runs against how most of the industry assembles a phone. CTO Chandler Hatton said the…

Miles Broadbent2 min read

02Deals · NVDA

Woot puts refurbished Alienware Aurora 16 within reach at $927

A refurbished Alienware 16 Aurora gaming laptop with Nvidia's RTX 5050 is available at Woot for $927 with the checkout code WOOTALIEN for new customers, against a retail price of $1,099.99 at Alienware's site. Returning Woot shoppers pay…

Desmond Choi2 min read

03Deals · NVDA

Nvidia's Hugging Face acquisition plan sends Huang's net worth toward $200 billion

Hugging Face became the stated acquisition target for Nvidia (NVDA) on Friday, lifting shares 1% and adding a few billion dollars to Jensen Huang's estimated net worth, which is now approac

Talia Greenwood2 min read

Frequently asked

How much is Curaleaf offering for Aurora Cannabis?

Curaleaf tabled an unsolicited $4-per-share cash-and-stock bid, though Aurora shares were trading around $3.48 at the time of the report.

Why does Curaleaf want to acquire Aurora?

The deal would accelerate Curaleaf's expansion into European medical cannabis markets like Germany, Poland, and the UK, aided by Aurora's Safari Flower Company, which brings EU-GMP certified cultivation and over 50 tons of annual production capacity.

Has Aurora's board accepted the offer?

No, Aurora's board has not accepted the terms and has signaled the price is too low, noting it falls below levels ACB traded at as recently as December 2025.

What do analysts think of the bid?

Wall Street analysts have said the bid undervalues Aurora's long-term medical business, with a consensus 'Moderate Buy' rating and price targets reaching as high as $5.71.

What happens next in the deal process?

The next definable event is a formal response from Aurora's board of directors, along with any amended terms from Curaleaf.